IRVINE, Calif., Dec. 16. 11, 2022 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize the treatment of patients, beginning by eye care, today announced that Tarsus will be added to the NASDAQ Biotechnology Index® (NASDAQ: NBI), effective December 19, 2022.

The NASDAQ Biotechnology Index is designed to track the performance of a collection of biotechnology and pharmaceutical companies listed on the Nasdaq stock market. Companies included in the index must meet eligibility criteria, including minimum market capitalization and average daily trading volume, among other criteria. The index is evaluated annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB). Due to this designation, shares of Tarsus will be included in the portfolios of the NASDAQ Biotechnology Index funds.

For more information on the NASDAQ Biotechnology Index, please visit here.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize patient treatment, starting with eye care. Tarsus is advancing its pipeline to address multiple diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology and infectious disease prevention. Tarsus is studying two experimental drugs in clinical trials. Its lead product candidate, TP-03, is a new drug that has demonstrated positive results in two pivotal trials for the treatment of Demodex blepharitis, and the New Drug Application for TP-03 has been accepted by the United States Food & Drug Administration (FDA) with a PDUFA target action date of August 25, 2023. TP-03 is also in development for the potential treatment of Meibomian Gland Disease, and currently being studied in a Phase 2a clinical trial. Additionally, Tarsus is developing TP-05, an oral non-vaccine drug for the potential prevention of Lyme disease, which is currently being studied in a Phase 2a clinical trial to assess its safety, tolerability and evidence of efficacy. ‘activity.

Forward-looking statements
Statements in this press release regarding future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements”. These statements include statements regarding the potential benefits of being included in the NASDAQ Biotechnology Index (NASDAQ: NBI). The words, but not limited to, “believe”, “contemplate”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “might “, “plan”, “potential”, “predict”, “project”, “should”, “target”, “shall” or “would”, or the negative form of these terms or other similar expressions are intended to identify forward-looking statements, although not all statements contain such identifying words or similar words. Actual results may differ materially from those indicated by these forward-looking statements due to a variety of important factors. In addition, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statement and are detailed from time to time in reports Tarsus files with the Securities and Exchange Commission, including Tarsus’ Form 10. -K for the fiscal year ended December 31, 2021 filed March 14, 2022 and the most recent quarterly filing of Form 10-Q filed with the SEC, which Tarsus incorporates by reference into this press release, copies of which are posted at its website and are available free of charge from Tarsus. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements contained in this press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Contact:
Adrienne Kemp
Senior Director, Corporate Communications
(949) 922-0801

Investor contacts:
David Nakason
Head of Investor Relations
(949) 620-3223

Source link

Leave A Reply